AQP4 and hematoma: In our study, both pharmacological inhibition and genetic knockout of AQP4 reduced the distribution of tracers and contrast agents, while treatment with an AQP4 agonist increased their distribution, ultimately influencing hematoma clearance and neurological outcomes.